In a 12-week randomized clinical trial involving 300 obese adults, participants receiving 1 mg daily of AOD-9604 lost an average of 2.6 kg (approximately 5.7 pounds) compared to 0.8 kg (1.8 pounds) in the placebo group
However, AOD 9604 therapy is not recommended for: Pregnant or breastfeeding individuals People with cancer history (because of the need for safety clearance due to the growth aspect) Individuals with uncontrolled chronic disease unless cleared by physician Always speak to your licensed healthcare provider before proceeding with peptide therapy to determine if its a fit for your health status and goals
And the molecular modifications that separate them, tiny changes at the amino acid level, create a gap in potency, convenience, and clinical results that surprises even seasoned researchers
The platelet-rich portion of your blood is then injected into your affected area
Tirzepatide is an FDA-approved prescription medication marketed as Mounjaro for type 2 diabetes mellitus and Zepbound for chronic weight management in adults with BMI 30 kg/m, or 27 kg/m with at least one weight-related comorbidity
